Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study
In a six-month, multicenter, open-label trial, de novo kidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid withdrawal with IL-2 receptor antibody (IL-2RA) induction, enteric-coated mycophenolate sodium (EC-MPS: 2160 mg/day to week 6, 1440 mg/day the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2014/171898 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401776515579904 |
|---|---|
| author | A. Thierry G. Mourad M. Büchler G. Choukroun O. Toupance N. Kamar F. Villemain Y. Le Meur C. Legendre P. Merville M. Kessler A.-E. Heng B. Moulin S. Queré F. Di Giambattista A. Lecuyer G. Touchard |
| author_facet | A. Thierry G. Mourad M. Büchler G. Choukroun O. Toupance N. Kamar F. Villemain Y. Le Meur C. Legendre P. Merville M. Kessler A.-E. Heng B. Moulin S. Queré F. Di Giambattista A. Lecuyer G. Touchard |
| author_sort | A. Thierry |
| collection | DOAJ |
| description | In a six-month, multicenter, open-label trial, de novo kidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid withdrawal with IL-2 receptor antibody (IL-2RA) induction, enteric-coated mycophenolate sodium (EC-MPS: 2160 mg/day to week 6, 1440 mg/day thereafter), and cyclosporine. Results from a 30-month observational follow-up study are presented. Of 166 patients who completed the core study on treatment, 131 entered the follow-up study (70 steroid avoidance, 61 steroid withdrawal). The primary efficacy endpoint of treatment failure (clinical biopsy-proven acute rejection (BPAR) graft loss, death, or loss to follow-up) occurred in 21.4% (95% CI 11.8–31.0%) of steroid avoidance patients and 16.4% (95% CI 7.1–25.7%) of steroid withdrawal patients by month 36 (P=0.46). BPAR had occurred in 20.0% and 11.5%, respectively (P=0.19). The incidence of adverse events with a suspected relation to steroids during months 6–36 was 22.9% versus 37.1% (P=0.062). By month 36, 32.4% and 51.7% of patients in the steroid avoidance and steroid withdrawal groups, respectively, were receiving oral steroids. In conclusion, IL-2RA induction with early intensified EC-MPS dosing and CNI therapy in de novo kidney transplant patients at low immunological risk may achieve similar three-year efficacy regardless of whether oral steroids are withheld for at least three months. |
| format | Article |
| id | doaj-art-860cddbf7ff4435bbf9f47a62c303fe3 |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-860cddbf7ff4435bbf9f47a62c303fe32025-08-20T03:37:42ZengWileyJournal of Transplantation2090-00072090-00152014-01-01201410.1155/2014/171898171898Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity StudyA. Thierry0G. Mourad1M. Büchler2G. Choukroun3O. Toupance4N. Kamar5F. Villemain6Y. Le Meur7C. Legendre8P. Merville9M. Kessler10A.-E. Heng11B. Moulin12S. Queré13F. Di Giambattista14A. Lecuyer15G. Touchard16Service de Néphrologie, Hémodialyse et Transplantation Rénale, Hôpital La Milétrie, et INSERM U927, CHU, 86021 Poitiers, FranceService de Néphrologie et Transplantation Rénale, Hôpital Lapeyronie, 371 rue du Doyen Gaston Giraud, 34295 Montpellier, FranceService de Transplantation Rénale, CHU Bretonneau, 2, Boulevard Tonnellé, 37044 Tours Cedex, FranceService de Néphrologie, Médecine Interne, Dialyse, Transplantation Rénale et Réanimation, Hôpital Sud, Avenue Laënnec, 80054 Amiens Cedex 1, FranceService de Néphrologie et Transplantation Rénale, Hôpital Maison Blanche, 45 rue Cognacq Jay, 51092 Reims Cedex, FranceService de Néphrologie-Transplantation, Hôpital de Rangueil, 1 rue Jean Poulhès, 31403 Toulouse Cedex 4, FranceService de Néphrologie, CHU Angers, 4 rue Larrey, 49033 Angers, FranceService de Néphrologie et Transplantation Rénale, Hôpital La Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest, FranceService de Néphrologie et Transplantation Rénale, Hôpital Necker, 161 rue de Sèvres, 75015 Paris, FranceService de Néphrologie et Transplantation Rénale, Hôpital Pellegrin, Place Amélie Raba Léon, 33076 Bordeaux, FranceService de Néphrologie et Transplantation Rénale, CHU de Nancy, rue du Morvan, 54511 Vandoeuvre les Nancy, FranceService de Néphrologie, Hôpital Gabriel Montpied, rue Montalembert, 63003 Clermont Ferrand Cedex 1, FranceClinique Médicale B, Hôpital Civil, 1 Place de l’Hôpital, 67091 Strasbourg Cedex, FranceUnité Immuno-Transplantation, Novartis Pharma SAS, rue Lionel Terray, 92500 Rueil-Malmaison, FranceUnité Immuno-Transplantation, Novartis Pharma SAS, rue Lionel Terray, 92500 Rueil-Malmaison, FranceUnité Immuno-Transplantation, Novartis Pharma SAS, rue Lionel Terray, 92500 Rueil-Malmaison, FranceService de Néphrologie, Hémodialyse et Transplantation Rénale, Hôpital La Milétrie, et INSERM U927, CHU, 86021 Poitiers, FranceIn a six-month, multicenter, open-label trial, de novo kidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid withdrawal with IL-2 receptor antibody (IL-2RA) induction, enteric-coated mycophenolate sodium (EC-MPS: 2160 mg/day to week 6, 1440 mg/day thereafter), and cyclosporine. Results from a 30-month observational follow-up study are presented. Of 166 patients who completed the core study on treatment, 131 entered the follow-up study (70 steroid avoidance, 61 steroid withdrawal). The primary efficacy endpoint of treatment failure (clinical biopsy-proven acute rejection (BPAR) graft loss, death, or loss to follow-up) occurred in 21.4% (95% CI 11.8–31.0%) of steroid avoidance patients and 16.4% (95% CI 7.1–25.7%) of steroid withdrawal patients by month 36 (P=0.46). BPAR had occurred in 20.0% and 11.5%, respectively (P=0.19). The incidence of adverse events with a suspected relation to steroids during months 6–36 was 22.9% versus 37.1% (P=0.062). By month 36, 32.4% and 51.7% of patients in the steroid avoidance and steroid withdrawal groups, respectively, were receiving oral steroids. In conclusion, IL-2RA induction with early intensified EC-MPS dosing and CNI therapy in de novo kidney transplant patients at low immunological risk may achieve similar three-year efficacy regardless of whether oral steroids are withheld for at least three months.http://dx.doi.org/10.1155/2014/171898 |
| spellingShingle | A. Thierry G. Mourad M. Büchler G. Choukroun O. Toupance N. Kamar F. Villemain Y. Le Meur C. Legendre P. Merville M. Kessler A.-E. Heng B. Moulin S. Queré F. Di Giambattista A. Lecuyer G. Touchard Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study Journal of Transplantation |
| title | Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study |
| title_full | Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study |
| title_fullStr | Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study |
| title_full_unstemmed | Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study |
| title_short | Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study |
| title_sort | three year outcomes in kidney transplant patients randomized to steroid free immunosuppression or steroid withdrawal with enteric coated mycophenolate sodium and cyclosporine the infinity study |
| url | http://dx.doi.org/10.1155/2014/171898 |
| work_keys_str_mv | AT athierry threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT gmourad threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT mbuchler threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT gchoukroun threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT otoupance threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT nkamar threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT fvillemain threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT ylemeur threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT clegendre threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT pmerville threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT mkessler threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT aeheng threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT bmoulin threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT squere threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT fdigiambattista threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT alecuyer threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy AT gtouchard threeyearoutcomesinkidneytransplantpatientsrandomizedtosteroidfreeimmunosuppressionorsteroidwithdrawalwithentericcoatedmycophenolatesodiumandcyclosporinetheinfinitystudy |